Drug Profile
ACU 3223
Alternative Names: ACU-3223; AG-787-14-2Latest Information Update: 07 Apr 2020
Price :
$50
*
At a glance
- Originator Acucela
- Developer Kubota Vision
- Class Eye disorder therapies; Retinoids
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Retinopathy of prematurity
Most Recent Events
- 01 Apr 2020 Acucela is now called Kubota Vision
- 16 Jul 2016 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinopathy-of-prematurity in USA (PO)